It is provided a method for stimulating the secretion of specialized pro-resolving mediators in a subject after the administration of a therapeutic phospholipid compositions such as CaPre®, wherein the composition also increases plasma levels of 17S-HDHA, PDX and 18RS-HEPE in the subject. Increased levels of protectins and resolvins are useful in protecting against many inflammatory-related diseases.

It is provided a method for stimulating the secretion of specialized pro-resolving mediators in a subject after the administration of a therapeutic phospholipid compositions such as CaPre®, wherein the composition also increases plasma levels of 17S-HDHA, PDX and 18RS-HEPE in the subject. Increased levels of protectins and resolvins are useful in protecting against many inflammatory-related diseases.

There are provided various compositions comprising monoglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.

There are provided various compositions comprising monoglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.

There are provided various compositions comprising monoglyceride(s) and cannabinoid(s). These compositions can be useful for increasing the life span of a subject; for increasing the disability-free life expectancy, for slowing down the ageing process of a subject; for increasing the mitochondrial OXPHOS of a subject; for decreasing the mitochondrial LEAK of a subject; for increasing the mitochondrial RCR or COUPLING EFFICIENCY of a subject; and for optimizing the mitochondrial functions of a subject.

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.

The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.

In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.